BIOMAT Database Logo BIOMAT Database Logo

Effective long-term alpha-interferon treatment for hypereosinophilic syndrome. 1995

G W Canonica, and G Passalacqua, and C Pronzato, and L Corbetta, and M Bagnasco
Department of Internal Medicine, Genoa University, Italy.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004804 Eosinophils Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin. Eosinophil
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon
D017681 Hypereosinophilic Syndrome A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs. Endocarditis, Loeffler's,Idiopathic Hypereosinophilic Syndrome,Leukemia, Eosinophilic,Loeffler's Endocarditis,Endocarditis, Loeffler,Hypereosinophilic Syndrome, Idiopathic,Loeffler Endocarditis,Endocarditis, Loefflers,Eosinophilic Leukemia,Eosinophilic Leukemias,Hypereosinophilic Syndromes,Hypereosinophilic Syndromes, Idiopathic,Idiopathic Hypereosinophilic Syndromes,Leukemias, Eosinophilic,Loefflers Endocarditis,Syndrome, Hypereosinophilic,Syndrome, Idiopathic Hypereosinophilic,Syndromes, Hypereosinophilic,Syndromes, Idiopathic Hypereosinophilic

Related Publications

G W Canonica, and G Passalacqua, and C Pronzato, and L Corbetta, and M Bagnasco
alpha-Interferon treatment for idiopathic hypereosinophilic syndrome.
March 1994, American journal of hematology,
G W Canonica, and G Passalacqua, and C Pronzato, and L Corbetta, and M Bagnasco
Alpha interferon for hypereosinophilic syndrome.
December 1994, American journal of hematology,
G W Canonica, and G Passalacqua, and C Pronzato, and L Corbetta, and M Bagnasco
Alpha-interferon for the hypereosinophilic syndrome.
February 1991, Annals of internal medicine,
G W Canonica, and G Passalacqua, and C Pronzato, and L Corbetta, and M Bagnasco
Interferon-alpha for the hypereosinophilic syndrome.
November 1990, Annals of internal medicine,
G W Canonica, and G Passalacqua, and C Pronzato, and L Corbetta, and M Bagnasco
Treatment of the hypereosinophilic syndrome with interferon-alpha.
July 1995, Annals of internal medicine,
G W Canonica, and G Passalacqua, and C Pronzato, and L Corbetta, and M Bagnasco
Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome.
March 2020, British journal of haematology,
G W Canonica, and G Passalacqua, and C Pronzato, and L Corbetta, and M Bagnasco
[Hypereosinophilic syndrome with pachyderma preceding lymphoma. Treatment with interferon alpha].
January 1991, Annales de dermatologie et de venereologie,
G W Canonica, and G Passalacqua, and C Pronzato, and L Corbetta, and M Bagnasco
Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome.
November 1994, Annals of internal medicine,
G W Canonica, and G Passalacqua, and C Pronzato, and L Corbetta, and M Bagnasco
[Alpha interferon treatment in idiopathic hypereosinophilic syndrome resistant to conventional therapy].
March 1996, Medicina clinica,
G W Canonica, and G Passalacqua, and C Pronzato, and L Corbetta, and M Bagnasco
Alpha-interferon in a case of hypereosinophilic syndrome.
February 1991, British journal of haematology,
Copied contents to your clipboard!